Inovio Pharmaceuticals
10480 Wateridge Circle
San Diego
California
92121
United States
Tel: 858-597-6006
Website: http://www.inovio.com/
149 articles with Inovio Pharmaceuticals
-
Please check out the biopharma industry's COVID-19 stories that are trending for April 27, 2021.
-
With the U.S. Food and Drug Administration’s vaccines advisory committee meeting being held today to discuss the Johnson & Johnson vaccine and blood clotting, there’s even more interest in what’s going on in the pandemic than usual. Here’s a look at some of the top stories.
-
COVID-19 News: Researchers Discover a New Variant, Antiviral Shows Promise in Hamsters and More
4/20/2021
Please check out the biopharma industry's COVID-19 stories that are trending for April 20, 2021. -
Clinical Catch-Up: April 12-16
4/19/2021
It was a particularly busy week for clinical trial news, in part because of several big medical conferences. Here’s a look. -
Shares of Inovio are climbing in early trading this morning after the company announced its DNA vaccine candidate for COVID-19 induced a robust T-cell response against multiple variants of the SARS-CoV-2 virus.
-
QIAGEN and INOVIO Expand Collaboration to Develop Next Generation Sequencing (NGS) Companion Diagnostic for INOVIO’s VGX-3100 for Advanced Cervical Dysplasia
2/24/2021
Liquid biopsy-based precision test guides patient selection and offers potential for cost-effective, non-invasive alternative to surgical removal of cervical lesions
-
INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia
2/24/2021
Liquid biopsy-based precision test guides patient selection and offers potential for cost-effective, non-invasive alternative to surgical removal of cervical lesions
-
INOVIO Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
1/25/2021
INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced the closing of its previously announced underwritten public offering of 20,355,000 shares of its common stock
-
INOVIO Announces Pricing of Public Offering of Common Stock - Jan 21, 2021
1/21/2021
INOVIO Pharmaceuticals, Inc., a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, announced the pricing of an underwritten public offering of 17,700,000 shares of its common stock at a public offering price of $8.50 per share.
-
INOVIO Announces Proposed Public Offering of Common Stock
1/20/2021
INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, including COVID-19, cancer and HPV-associated diseases, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 17, 2020.
-
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
-
Pennsylvania-based Inovio said the regulatory agency has additional questions about the Phase II/III trial regarding the vaccine candidate itself, known as INO-4800, as well as the company’s Cellectra 2000 delivery device.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 9, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 1, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 26, 2020.
-
Inovio’s development issues for its vaccine candidate have become mired in a conflict with the contract manufacturing organization it has worked with on previous projects.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 5, 2020.
-
May 2020 Deadline Approaching for Inovio Pharmaceuticals (INO) Class Action
5/5/2020
Sokolove Law announces an investigation into a securities class action lawsuit filed against Inovio Pharmaceuticals (NASDAQ: INO) on behalf of shareholders. INO investors that purchased 20,000 shares or more between February 14 to March 9, 2020 and are interested in learning more about the class action lawsuit should call 800-974-3478 to explore their legal rights
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 1, 2020.